Allergan GI Corp.

Pfizer has increased its stake in Rhythm Pharmaceuticals. Pfizer has increased its stake in Rhythm Pharmaceuticals . According to an Oct. 18 filing with the U.S. Securities and Exchange Commission, Pfizer acquired 1,427,639 shares of Rhythm’s common stock. That amounts to about a 5.4 percent stake in the company. In total, Pfizer owns 26,226,640 shares of Common Stock, according to the SEC report. Barbara Dalton , a vice president of Venture Capital at Pfizer, told BioSpace that the New York-based pharma giant had been a longtime investor in Rhythm and supported its initial public offering. “Pfizer ventures was a long time investor in Rhythm and like all other private investors supported their IPO,” Dalton said in an email to BioSpace correcting an earlier report of when Pfizer acquired stock in Rhythm. In September, Rhythm announced it was seeking to raise about $115 million in an Initial Public Offering of $17 per share. The stock made its debut on Oct. 5 and quickly climbed to $30 per share, which yielded the company about $120 million. Since its debut though, prices have declined to $23.86 per share. Rhythm’s lead drug candidate setmelanotide is showing some clinical promise in the treatment of obesity caused by rare diseases. Rhythm went public a few months after it announced positive initial results from an ongoing Phase Ia clinical trial evaluating the pharmacokinetics and tolerability of an extended-release formulation of setmelanotide. Rhythm’s lead drug, setmelanotide is a novel melanocortin-4 receptor (MC4R) agonist being developed for the treatment of rare genetic disorders of obesity. The drug is delivered as a once-per-week subcutaneous injection. The obesity targets the company is taking aim at are caused by genetic deficiencies in the MC4 pathway, a biological pathway in people that regulates weight by increasing energy expenditure and reducing appetite. The Phase Ia trial is studying the pharmacokinetics and tolerability of three doses of setmelanotide in healthy obese patients. Setmelanotide is also being studied in a Phase II trial for the treatment of obesity caused by Bardet-Biedl syndrome (BBS), a monogenic disorder that causes severe obesity and an insatiable appetite. Patients with the rare disease can also experience vision loss and kidney abnormalities. Additionally, Rhythm is studying setmelanotide in a Phase III trial for the treatment of pro-opiomelanocortin (POMC) deficiency obesity, an ultra-rare genetic disorder associated with severe, early-onset obesity and unrelenting, abnormally increased appetite (hyperphagia). Rhythm also has setmelanotide trials underway for the treatment of LepR deficiency obesity, Prader-Willi syndrome and Alström syndrome. Last year, Rhythm’s sister company Motus Therapeutics, Inc. was acquired by Allergan for $200 million. Allergan struck after Motus’ drug candidate relamorelin (RM-131) , a ghrelin agonist, passed a Phase IIb efficacy trial for diabetic gastroparesis with flying colors. Trial results indicate patients taking the treatment for 12 weeks saw a 75 percent reduction of vomiting and abdominal pain in the targeted population of diabetic patients.

October 27, 2016 By Alex Keown , BioSpace.com Breaking News Staff DUBLIN – Allergan continues to build up its pipeline through a string of acquisitions. This time the company struck a $200 million deal to snag Motus Therapeutics, Inc. in an effort to shore up its gastrointestinal therapies. Allergan struck after Motus’ drug candidate relamorelin (RM-131) , a ghrelin agonist, after the drug passed a Phase IIb efficacy trial for diabetic gastroparesis with flying colors. Trial results indicate patients taking the treatment for 12 weeks saw a 75 percent reduction of vomiting and abdominal pain in the targeted population of diabetic patients. Motus is a wholly-owned subsidiary of Rhythm Holding Company, LLC . The U.S. Food and Drug Administration granted Fast Track review status to relamorelin for the treatment of diabetic gastroparesis. The drug is injectable, which is a benefit to patients as many of them cannot successfully ingest drugs due to the amount of vomiting they endure. David Nicholson , Allergan’s executive vice president of Global Research and Development, said the company intends to push relamorelin into a pivotal Phase III trial based off the successful Phase IIb and an earlier Phase IIa trials. There has not been a drug approved for gastroparesis by the FDA since 1983. “Patients with diabetic gastroparesis suffer greatly and have very limited treatment options,” Michael Camilleri , a gastroenterologist at Mayo Clinic who was a clinical trial adviser, said in a statement. “The findings in this trial support initiating Phase III clinical trials to confirm these Phase IIb results with relamorelin for the treatment of moderate to severe diabetic gastroparesis. Under terms of the deal, Allergan will pay the exercise price of $200 million at closing to Rhythm Holding, Motus’ parent company. Rhythm Holding will be eligible for a contingent payment upon first commercial sale of relamorelin. Allergan previously made $47 million in payments related to the option-to-acquire Motus and the relamorelin Phase IIb clinical trial. Completion of Allergan’s acquisition of Motus Therapeutics is expected to occur by the end of 2016 subject to customary closing conditions. Bill Meury , Allergan’s chief commercial officer, told Enpoints relamorelin has the potential to be “a flagship for us in gastroenterology in what could be a multibillion dollar drug market.” According to the data, relamorelin was safe and well-tolerated in the phase IIb study. There was some evidence of dose-related adverse events related to worsening of glycemic control in some patients. In the wake of Allergan’s merger with Pfizer falling apart earlier this year, the Irish company has been aggressive in its M&A activities. So far the company has struck a $60 million upfront deal to acquire gene therapy company Retrosense Therapeutics . In August, the company bagged the Bay Area’s ForSight Vision5 to gain that company’s glaucoma product. In April, Allergan acquired Boston-based Topokine Therapeutics and its lead product, XAF5, a first-in-class topical agent to treat steatoblepharon, better known as bags under the eyes. One day after the Pfizer deal fell through, Allergan entered into an agreement with Heptares Therapeutics for exclusive global rights to a portfolio of novel subtype-selective muscarinic receptor agonists for the treatment of several neurological disorders, including Alzheimer’s disease. Allergan also Allergan struck a $639 million deal to acquire Vitae Pharmaceuticals and its experimental oral psoriasis treatment, VTP-43742 and other dermatological products. Brent Saunders , Allergan’s chief executive officer, said the deals the company has focused on since the Pfizer deal fell apart, are for products that Allergan believes it can grow and develop into strong revenue generators.